Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses the potential use of thermal paper receipts, which contain estrogen, as a treatment for hair loss. Participants humorously debate its effectiveness compared to established treatments like Minoxidil and finasteride.

A 22-year-old male experienced hair loss potentially linked to escitalopram, which stopped after switching to vortioxetine. His depressive symptoms improved with continued treatment.

Bryan Johnson shared his hair loss treatment, which mainly relies on minoxidil and finasteride. Some users are skeptical of his results, while others appreciate his efforts in anti-aging and hair loss research.

The potential of using a specific antibody, HMI-115, as a treatment for hair loss alongside traditional treatments such as minoxidil and finasteride. The user suggests trying either a 240 mg or 30 mg dose to see if it works.

A user reported hair regrowth after taking D3 vitamin pills and using anti-hair fall shampoo for four months. They were later advised to use 10% minoxidil, a hair spray, and a general vitamin pill containing iron, B9, and B12.

Saw Palmetto is not effective for hair loss treatment and is not a recommended alternative to finasteride due to its inability to significantly inhibit DHT.

KOSHINE826 is a new anti-hair loss and hair growth solution that claims to effectively control oil, reduce hair fall, and promote real hair growth. It targets androgenetic alopecia by inhibiting DHT and has shown promising results in clinical trials.

People discuss using Tretinoin for both skin anti-aging and improving hair loss treatments. They mention combining Tretinoin with Minoxidil to enhance its effectiveness for hair growth.

A user shared their 3-month progress using 1mg oral finasteride daily and 5% topical minoxidil twice daily, along with Pura D’Or anti-thinning shampoo and a scalp massager. They noticed initial worsening but later saw hair follicle recovery.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.